Amplia Therapeutics Ltd ATX-AU:ASX

*Data is delayed | Exchange | AUD
Last | 04/30/24 AET
0.062UNCH (UNCH)
52 week range
0.05 - 0.11
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.062
  • 52 Week High0.11
  • 52 Week High Date05/01/23
  • 52 Week Low0.05
  • 52 Week Low Date04/24/24

Key Stats

  • Market Cap8.49M
  • Shares Out199.61M
  • 10 Day Average Volume223,961.1
  • Dividend-
  • Dividend Yield-
  • Beta0.53
  • YTD % Change-20.26

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.062
  • 52 Week High0.11
  • 52 Week High Date05/01/23
  • 52 Week Low0.05
  • 52 Week Low Date04/24/24
  • Market Cap8.49M
  • Shares Out199.61M
  • 10 Day Average Volume223,961.1
  • Dividend-
  • Dividend Yield-
  • Beta0.53
  • YTD % Change-20.26

RATIOS/PROFITABILITY

  • EPS (TTM)-0.02
  • P/E (TTM)-2.70
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Amplia Therapeutics Ltd

 

Profile

MORE
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company’s pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical...
Warwick Tong
Non-Executive Independent Chairman of the Board
Christopher Burns
Chief Executive Officer, Managing Director, Director
Hamish George
Chief Financial Officer
Address
Level 17, 350 Queen Street
Melbourne, VIC
3000
Australia